We are live on ! Find out more
VEA

Virtus ETF Advisers Portfolio holdings

AUM $215M
1-Year Est. Return 53.68%
This Fund
S&P 500
This Quarter Est. Return
+15.01%
1 Year Est. Return
+53.68%
3 Year Est. Return
+121.72%
5 Year Est. Return
+144.54%
10 Year Est. Return
+633.35%
AUM
$115M
AUM Growth
+$35.6M
Cap. Flow
+$33.1M
Cap. Flow %
28.7%
Top 10 Hldgs %
16.88%
Holding
267
New
23
Increased
109
Reduced
60
Closed
21

Top Buys

Rank Stock Value
1
TLT icon
iShares 20+ Year Treasury Bond ETF
TLT
+$1.39M
2
INDA icon
iShares MSCI India ETF
INDA
+$872K
3
IOVA icon
Iovance Biotherapeutics
IOVA
+$767K
4
JNCE
Jounce Therapeutics, Inc. Common Stock
JNCE
+$708K
5
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$648K

Top Sells

Rank Stock Value
1
UPW icon
ProShares Ultra Utilities
UPW
+$1.11M
2
VDE icon
Vanguard Energy ETF
VDE
+$755K
3
RXDX
Ignyta, Inc.
RXDX
+$612K
4
FTEC icon
Fidelity MSCI Information Technology Index ETF
FTEC
+$430K
5
JUNO
Juno Therapeutics, Inc.
JUNO
+$359K

Sector Composition

Rank Sector Weight
1 Healthcare 78.8%
2 Financials 0.81%
3 Technology 0.51%
4 Consumer Discretionary 0.44%
5 Communication Services 0.32%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RDUS
26
DELISTED
Radius Health, Inc.
RDUS
$1.11M 0.97%
31,013
-1,850
-6% -$66.8K
MDCO
27
DELISTED
Medicines Co
MDCO
$1.1M 0.95%
33,271
-1,946
-6% -$60.8K
KPTI icon
28
Karyopharm Therapeutics
KPTI
$168M
$1.09M 0.95%
5,422
+2,957
+120% +$590K
VNDA icon
29
Vanda Pharmaceuticals
VNDA
$312M
$1.08M 0.94%
64,040
-3,773
-6% -$63.2K
LOXO
30
DELISTED
Loxo Oncology, Inc
LOXO
$1.08M 0.94%
9,346
+4,922
+111% +$524K
NBIX icon
31
Neurocrine Biosciences
NBIX
$17.7B
$1.07M 0.93%
12,899
-753
-6% -$63.6K
XNCR icon
32
Xencor
XNCR
$1.44B
$1.07M 0.92%
35,554
+19,240
+118% +$503K
ITCI
33
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$1.05M 0.91%
50,088
+26,986
+117% +$526K
VDE icon
34
Vanguard Energy ETF
VDE
$10.1B
$1.05M 0.91%
11,398
-7,801
-41% -$755K
EPZM
35
DELISTED
Epizyme, Inc
EPZM
$1.05M 0.91%
59,330
+31,789
+115% +$537K
KURA icon
36
Kura Oncology
KURA
$922M
$1.04M 0.9%
55,283
+29,635
+116% +$577K
VRTX icon
37
Vertex Pharmaceuticals
VRTX
$121B
$1.03M 0.9%
6,334
-484
-7% -$79.1K
ACOR
38
DELISTED
Acorda Therapeutics
ACOR
$1.03M 0.9%
364
-21
-5% -$62.9K
AKCA
39
DELISTED
Akcea Therapeutics Inc
AKCA
$1.01M 0.87%
39,351
+21,280
+118% +$458K
VYGR icon
40
Voyager Therapeutics
VYGR
$187M
$1M 0.87%
53,407
+29,821
+126% +$645K
AGEN
41
Agenus
AGEN
$249M
$1M 0.87%
10,829
+5,823
+116% +$517K
QURE icon
42
uniQure
QURE
$2.68B
$999K 0.87%
42,504
+22,662
+114% +$494K
CTMX icon
43
CytomX Therapeutics
CTMX
$705M
$992K 0.86%
34,876
+18,817
+117% +$537K
MGNX icon
44
MacroGenics
MGNX
$235M
$988K 0.86%
39,254
+21,197
+117% +$515K
VNQ icon
45
Vanguard Real Estate ETF
VNQ
$39.9B
$976K 0.85%
12,936
+4,475
+53% +$342K
ACHN
46
DELISTED
Achillion Pharmaceuticals
ACHN
$973K 0.84%
262,284
+141,020
+116% +$462K
MYOK
47
DELISTED
MyoKardia, Inc. Common Stock
MYOK
$957K 0.83%
19,602
+10,155
+107% +$528K
DVAX
48
DELISTED
Dynavax Technologies
DVAX
$951K 0.83%
47,898
-2,828
-6% -$48.8K
GILD icon
49
Gilead Sciences
GILD
$161B
$946K 0.82%
12,546
-742
-6% -$59K
AVXS
50
DELISTED
AveXis, Inc. Common Stock
AVXS
$938K 0.81%
7,590
+4,126
+119% +$490K
1
2
3 4 5

Similar funds

NCM
NEXTBio Capital Management Menlo Park, California $215M AUM
SSA
SSA Swiss Advisors Zurich $216M AUM 17.86% 1-Year Est. Return
LIWM
Long Island Wealth Management Melville, New York $216M AUM 14.59% 1-Year Est. Return
VFG
V2 Financial group Naperville, Illinois $215M AUM 15.18% 1-Year Est. Return
IAM
Impala Asset Management Palm Beach, Florida $215M AUM 86.77% 1-Year Est. Return
1M
1248 Management Kansas City, Missouri $216M AUM 12.29% 1-Year Est. Return
GC
GatePass Capital Independence, Ohio $214M AUM 29.83% 1-Year Est. Return
ALS
Andrew L. Share $214M AUM 14.75% 1-Year Est. Return

Virtus ETF Advisers's Q1 2018 Portfolio in Review

As of Q1 2018, Virtus ETF Advisers held 267 positions worth $115M, up 45% from $79.7M the previous quarter. Its ten largest holdings account for 17% of the portfolio.

Virtus ETF Advisers deployed $33.1M of net new capital in Q1 2018, opening 23 new positions and adding to 109 existing holdings. Its largest new stake was Sociedad Química y Minera de Chile: 2,101 shares worth $103K.

By sector, the portfolio is most concentrated in Healthcare at 79% of assets, up from 71% a quarter earlier, followed by Financials and Technology.

On the sell side, the largest reduction was Vanguard Energy ETF, an estimated $755K trimmed.

  • Virtus ETF Advisers's largest Q1 2018 buy was Sociedad Química y Minera de Chile: 2,101 shares worth $103K.
  • Virtus ETF Advisers added most to iShares 20+ Year Treasury Bond ETF in Q1 2018, an estimated $1.39M increase.
  • Virtus ETF Advisers's biggest Q1 2018 reduction was Vanguard Energy ETF, cutting an estimated $755K.
  • Virtus ETF Advisers fully exited ProShares Ultra Utilities in Q1 2018, selling an estimated $1.11M.
  • Virtus ETF Advisers's ten largest holdings make up 17% of its $115M portfolio in Q1 2018.
  • Virtus ETF Advisers opened 23 new positions and closed 21 in Q1 2018.
  • Virtus ETF Advisers's portfolio value rose 45% quarter-over-quarter to $115M.

Based on Virtus ETF Advisers's 13F filing for Q1 2018, filed 14 May 2018.